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Metalloproteinase Shedding of Fas Ligand
Regulates -Amyloid Neurotoxicity
FasL interactions on A neurotoxicity (Figure 1E). The
generalized lympho-proliferative disorder seen in gld
mice is due to a point mutation near the carboxyl termi-
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in a loss of function [7, 8]. CGN cultures isolated from gld10355 Science Center Drive
San Diego, California 92121 mice did not show any significant increase of apoptotic
nuclei in response to A treatment for 3–5 days (Figure2 Biomedical Sciences Division
The University of California, Riverside 1F). In contrast, companion wild-type (WT) cultures con-
sistently showed more apoptotic nuclei when treatedRiverside, California 92521-0121
3 Discovery Biology with A for 5 days. These findings, taken together with
a recent report [3], demonstrate that Fas-FasL interac-Pfizer Global Research and Development
Sandwich tions contribute to A neurotoxicity.
It has been reported that Fas expression is elevatedKent CT13 9NJ
United Kingdom in the brains of Alzheimer’s patients [9]. We have found
that mRNA (Figure 2A) and protein (Figure 2B) levels of
the cognate ligand FasL increase after A treatment
between 12 and 24 hr. The Fas binding region of FasLSummary
is often shed from cells by metalloproteinases, such as
MMP-7, to release soluble FasL (sFasL), which de-Extracellular deposits of -amyloid (A) peptide closely
creases the concentration of membrane-bound FasLmatch areas of neuronal loss in, and are a postmortem
and has been reported to prevent apoptosis in somediagnostic indicator of, Alzheimer’s disease. Neuronal
cancer cells [5]. Nagata and colleagues have shown thatcultures treated with fibrillar A can be protected from
sFasL is inactive and suggested that it may antagonizeneurotoxicity by caspase-8 inhibition or the expression
FasL-mediated apoptosis [4]. We therefore examinedof dominant-negative FADD, both of which are compo-
the effects of FasL shedding on A neurotoxicity.nents of the Fas death receptor pathway [1, 2], and
GM6001 (Ilomastat) can inhibit all matrix metalloprotei-neurons with defective Fas and FasL are resistant to
nases (MMPs) and a-disintegrin-and-a-metalloprotei-A neurotoxicity [3]. The receptor binding region of
nases (ADAMs) by interfering with an essential Zn2FasL can be shed from cells by metalloproteinases,
binding motif in their catalytic domains [10]. Althoughand this process greatly reduces its proapoptotic ac-
the inclusion of GM6001 had little effect on CGN culturestivity [4, 5]. Here, we show that factors affecting the
after 4 days, it acted synergistically with A to dramati-shedding of membrane-bound FasL significantly im-
cally increase neurotoxicity starting at 2 days (Figurepact A neurotoxicity. A broad-spectrum metallo-
3A). Membrane-bound (i.e., unshed) FasL protein wasproteinase inhibitor, GM6001/Ilomastat, acted syner-
found to increase after treatment with A and GM6001gistically with A to enhance neurotoxicity through a
(Figure 3B). A alone increased the relative expressionFasL-dependent mechanism. The disruption of ADAM-
of FasL 1.6-fold by 2 days, while the combination of Abased metalloproteinase activity was likely responsi-
and GM6001 more than tripled (3.1) membrane-boundble, as MMP-inhibiting TIMPs had no such effect. In
FasL levels. Conversely, A plus recombinant MMP-7contrast, enhanced FasL shedding, by recombinant
decreased the level of membrane-bound FasL (0.7)MMP-7, completely protected neurons from A neuro-
below that of media-treated controls.toxicity. These findings suggest that factors that affect
We then compared the GM6001 response in neuronsmetalloproteinase-mediated shedding of FasL may
from WT and FasL-defective gld mice (Figure 3C). Afterplay a role in the etiology of Alzheimer’s disease and
5 days, GM6001 dramatically enhanced the neurotoxicmay provide an avenue for therapeutic intervention.
effects of A in WT cultures, but it did not affect the
resistance of gld neurons to A. Similarly, CGNs cultured
Results and Discussion with FasFc were protected from the synergistic effects
of A and GM6001 (Figure 3D). In contrast, TNFR(p60)Fc
To examine the role of Fas-FasL interactions in A- [6] had no protective effect. These findings indicate that
mediated neuronal death, we employed recombinant FasL-mediated cell death is responsible for the syner-
FasFc to block FasL function [6]. CGN cultures treated gistic effects observed with A and GM6001.
with A1–40 for 5 days displayed significant neurotoxicity, We next examined if decreased FasL shedding might
as indicated by increased percentages of apoptotic nu- be facilitated by higher expression of naturally occurring
clei (Figures 1A and 1B). However, cultures treated with tissue inhibitors of metalloproteinases (TIMPs). We as-
A in combination with FasFc were protected from A sessed RNA levels of the four known mammalian TIMPs
neurotoxicity (Figure 1C), while control IgG had no such [11] in CGN cultures treated with A (Figure 3E). A
effect (Figure 1D). Quantification of apoptotic nuclear treatment did not substantially increase the mRNA level
morphology showed a significant effect of blocking Fas- of any of these TIMPs. The impact on A neurotoxicity
of TIMP-1, TIMP-2, and TIMP-3 versus GM6001 was
investigated in the experiment shown in Figure 3F. Sur-4 Correspondence: dgreen5240@aol.com
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Figure 1. Fas Signaling Is Required for A
Neurotoxicity
Cerebellar neuron cultures were treated for 5
days, fixed, and stained with Hoecsht 33258,
and the nuclei were visualized with an in-
verted fluorescence video-microscope at 40.
(A) Control cultures show many large round
nuclei, scored as viable cells. The scale bar
represents 10 M in all panels.
(B) Treatment with 100 g/ml A1–40 for 5 days
decreased the number of viable nuclei and
increased the number of condensed, frag-
mented, and bright nuclei, which were scored
as apoptotic. Small individual fragments were
considered debris and were not used in the
calculations.
(C) Inclusion of FasFc (30 g/ml) protected
neurons from A neurotoxicity.
(D) Non-specific IgG had no effect on A neu-
rotoxicity.
(E) Apoptotic and viable nuclei were scored
from three separate images, and the per-
centages of three wells each in two separate
experiments were pooled. Using one-way
analysis of variance (ANOVA, with 95% confi-
dence), we found the difference between A
and AFasFc conditions to be statistically
significant (indicated by an asterisk). The er-
ror bars represent standard errors of the
mean.
(F) WT and FasL-defective (gld) neurons were
treated with 100 g/ml A1–40 for 3–5 days,
and nuclear morphology was scored as de-
scribed. Using one-way ANOVA (95% confi-
dence), we found the percentage of apoptotic
nuclei in the WT 5-day A-treated cultures
to be statistically significant (indicated by an
asterisk) when compared with WT 5-day con-
trol, gld 5-day control, or gld 5-day A-treated
cultures. The error bars represent standard
errors of the mean.
prisingly, the TIMPs did not have synergistic effects with age of A, since overnight incubations of the two
followed by reverse-phase HPLC analysis showed noA, despite being potent inhibitors of MMPs. Therefore,
the neurotoxic response to A is not mediated by an differences in peak distribution between control A pep-
tides and those incubated with MMP-7 (data not shown).induction of TIMP expression. Although TIMP-3 has
been established as an inhibitor of TNF--cleaving en- The release of sFasL by MMP-7 was examined in
media from treated cultures after 5 days (Figure 5B).zyme (TACE/ADAM-17) [12], some of the ADAMs that
were not inhibited by TIMPs may participate in FasL FasL was detected in the media of cultures treated with
A plus MMP-7 and, to a lesser extent, in those treatedshedding. The synergistic effects of A with GM6001,
but not the TIMPs, may be due to inhibition of ADAMs. with MMP-7 alone. However, the lack of sFasL in control
and A-treated lanes suggests that other proteinasesFinally, we used MMP-7 to experimentally increase
FasL by shedding [5]. Treatment of neuronal cultures may cleave or degrade FasL. MMP-7 cleavage of FasL
releases sFasL from the cell and would prevent suchwith A alone increased the appearance of morphologi-
cally apoptotic cells (Figures 4A and 4C) and nuclei (Fig- proteolysis if it were restricted to the cell membrane,
as might be expected with ADAMs, which are integralures 5B and 5D). However, MMP-7 completely protected
neuron cultures from A neurotoxicity (Figures 4E and membrane proteins [13].
A growing body of work suggests roles for Fas-medi-4F). Although the cells appeared slightly smaller, high
magnification of the nuclei revealed that they were not ated apoptosis in neuronal death during development
[14–17] and after CNS injury [18, 19]. The regulationapoptotic (not shown). In contrast, GM6001 greatly en-
hanced the neurotoxic effects of A (Figures 4G and of FasL by metalloproteinases in A neurotoxicity may
reflect the role of FasL in immune privilege [20, 21].4H). Quantification showed the reciprocal effects of in-
creased and decreased FasL shedding on A neurotox- Neurons may express higher amounts of FasL in re-
sponse to stimuli that represent damage to the bloodicity (Figure 5A). MMP-7 does not protect cells by cleav-
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sistently greater than 95% neurons. Cells were maintained and
treated in a humidified incubator at 37C with 8% CO2.
Real-Time PCR
Neuron cultures were rinsed three times with PBS, and then total
RNA was isolated with 400 l Trizol-LS. Reverse-transcribed cDNA
was made from 1 g of each RNA sample and was used for all
subsequent real-time PCR reactions. Specific primer sequences
are available upon request. Cycles were run on a PE Biosystems
Taqman, and CYBR green was used for fluorescent detection of
dsDNA, as per the manufacturer’s instructions. Normalization of the
initial RNA composition was calculated from concurrent runs with
primers specific for actin. Triplicates were performed with each
primer set for each RNA sample. The mid-linear range was used to
establish the threshold for each oligonucleotide set. After normaliza-
tion and the calculation of differences within each time-point experi-
ment subset, all data from each time point were pooled to calculate
differences.
A Treatments
A1–40 was purchased from BachemAG, resuspended in water to 6
mg/ml, then diluted to 1 mg/ml with PBS and allowed to preincubate
at 37C for 3–5 days before use. Preincubated peptide was added
to neurobasal media to achieve 25, 50, 75, or 100 g/ml A, and it
was placed on cells for 1–5 days. In FasFc studies, cultures were
preincubated in media with 30 M FasFc or IgG for 12 hr, and 30
M was also added to the treatment media. Recombinant human
MMP-7 (Calbiochem) was diluted into treatment media at 1.5 and
15 U/ml immediately prior to use. GM6001 (Chemicon) was used
at final concentrations of 22–25 M. Recombinant human TIMP-1
(Chemicon), recombinant human TIMP-2 (Chemicon), and recombi-
nant mouse TIMP-3 (Chemicon) were used at final concentrations
of 500 ng/ml.
Figure 2. A Treatment Alters FasL Expression
(A) An anti-FasL immunoblot of whole-cell lysates from cerebellar Apoptosis Assays
neuron cultures treated with 100 g/ml A1–40 or media control for Neurons were fixed for 30 min with 4% formalin/0.1% glutaraldehyde
2 days shows bands of the expected 31 kDa size for FasL. Blots in PBS. After washing with PBS, nuclei were stained with DAPI (2.5
were reprobed for actin to confirm equal loading. g/ml in PBS) or Hoechst (10 M in PBS) for 30 min, washed, and
(B) Real-time PCR analysis of the FasL RNA message after 1, 12, imaged with an inverted fluorescence video-microscope. A total of
24, and 48 hr of A treatment. 6–12 images of each well were captured. Statistical analysis was
performed by one-way ANOVA.
Immunoblotsbrain barrier, and these changes may limit immune infil-
Total protein extracts were prepared by withdrawing the media,tration by creating a local area that is immune sup-
gently rinsing three times with PBS, and then adding hot samplepressed by the expression of FasL. Consistent with this
buffer directly to the wells. After scraping the wells with a rubber
idea, myelin basic protein-specific T cells produce only policeman, samples were collected, and sample buffer was added
transient encephalomyelitis in WT mice but prolonged to reach a final volume typically 300l per sample. DNA was sheared
progressive disease in FasL-defective gld mice [22]. by repeated aspiration into a 1-ml syringe through a 27G needle,
followed by centrifugation through a 0.1-M spin filter. Equal vol-Therefore, the expression of functional FasL in the brain,
umes of sample were run on 4%–15% or 4%–20% gradient gelsunder regulation by metalloproteinases, may have con-
and were blotted to Hybond-ECL overnight in transfer buffer (20trasting effects to protect or damage neuronal cells in
mM Tris-HCl, 150 mM glycine, 20% MeOH). For Ponceau staining,
different settings. a 0.1% solution (Sigma) was used and destained with repeated
washes with water. Blots were blocked with 3% BSA and 5% milk
in PBST (0.05%–0.1%) for 1–2 hr and were probed overnight at 4CExperimental Procedures
in 1% BSA and 1.75% milk in PBST. Following three 5-min washes
in PBST, species-specific HRP-conjugated secondary antibodiesNeuronal Cultures
were incubated for 1 hr at room temperature. Three 5-min washes inC57BL/6J and congenic B6smn.C3H-FasLgld mice from Jack-
PBST were followed by chemiluminescent exposure of film. Relativeson Labs were used for cerebellar neuron preparations at 7 days
FasL levels were determined from scanned films and were analyzedof age. Cerebellum tissue was minced with a razor and incubated
with NIH image, normalized to corresponding anti-actin blots.in 0.05% trypsin/EDTA in PBS (0.25% sucrose) for 7 min. Trypsin
inhibitor was added, and material was pelleted at 1000  g for 3
min. Pellets were washed in 15 ml PBS (0.25% sucrose). The final Reagents
Anti-FasL antibodies (Oncogene, used at 1:50) were employed forpellets were resuspended in 1 ml PBS (0.25% sucrose) and were
triturated with coarse, then fine, fire-polished Pasteur pipettes. Cells immunoblots, and the identity of the FasL band that was resolved
was confirmed (not shown) with other anti-FasL antibodies (Phar-were diluted in 10 ml complete neurobasal media (see below) and
were drained through a 70 M sieve. Viable cells were assessed by mingen, used at 1:1000; Santa Cruz Biotech, used at 1:1000). HRP-
conjugated secondary antibodies were purchased from Amershamtrypan blue exclusion and were plated onto poly-L-lysine-coated
plates in neurobasal media containing B27 supplement (Invitrogen), (used at 1:2000) and Pierce (used at 1:10000). Chemiluminescent
reagents were purchased from Pierce; Neurobasal media, B27 sup-25 mM KCl, penicillin, streptomycin, and L-glutamine at 2.5  105/
cm2. Cytosine arabinoside (5 M) was added after 48 hr, and half plement, penicillin, streptomycin, L-glutamine, and RT reagents
were purchased from GIBCO. Poly-L-lysine was purchased fromthe media was changed every 2 days thereafter. Cultures were con-
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Figure 3. Synergistic Effects of GM6001 on
A Neurotoxicity
(A) Primary neurons were treated for 1–4 days
with control media (open circle) or media con-
taining A1–40 (100 g/ml; filled circle), GM6001
(22 M; open triangle), or AGM6001 (filled
triangle). Percentages of apoptotic nuclei were
calculated from DAPI-stained cultures and
were plotted.
(B) An immunoblot of a whole-cell lysate from
primary neurons treated for 2 days with con-
trol media, A1–40 (100 g/ml), AGM6001
(22 g/ml), or AMMP-7 (1.5 U/ml) and
probed with anti-FasL shows bands at the
expected 31 kDa. A reprobe of the blot with
an actin-specific antibody is shown below.
Relative FasL expression was calculated
from scans of the films with actin to normalize
all lanes.
(C) The effects of GM6001A1–40 were com-
pared with WT and gld neuron cultures after
5 days. The percentage of apoptotic nuclei
scored show the importance of FasL to this
synergy. Using one-way ANOVA (95% confi-
dence), we found a statistically significant (in-
dicated by an asterisk) difference between
AGM6001-treated WT and gld cultures.
(D) The synergistic effects of GM6001A
can be blocked by interfering with Fas-FasL
engagement by using FasFc. The percent-
ages of apoptotic nuclei after 3-day treat-
ments are shown. Using one-way ANOVA
(95% confidence), we determined that there
is a statistically significant (indicated by an
asterisk) difference between AGM6001
and AGM6001FasFc conditions, but no
significant difference between AGM6001
and AGM6001IgG conditions. The error
bars represent standard errors of the mean.
(E) Real-time PCR analysis of TIMP RNA lev-
els in neurons treated with A1–40 (100 g/ml)
for 0, 24, or 48 hr.
(F) Lack of synergistic effects between TIMPs
and A neurotoxicity. The percentages of
apoptotic nuclei after 3-day treatments with
A1–40 (100 g/ml) and TIMP-1 (500 ng/ml),
TIMP-2 (500 ng/ml), or TIMP-3 (500 ng/ml)
were compared to A and GM6001 (25 M).
Using one-way ANOVA (95% confidence), we
found statistically significant differences (in-
dicated by an asterisk) between the percent-
age of apoptotic nuclei in AGM6001 treat-
ment versus ATIMP-1, ATIMP-2, or
ATIMP-3. The error bars represent stan-
dard errors of the mean.
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Figure 5. Complementary Effects of Changing Metalloproteinase
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Figure 4. MMP-7 Protects Neurons from A Neurotoxicity
(A) The percentages of apoptotic and nonapoptotic nuclei from six
Paired Hoffman-optics and UV excitation images of neurons show images in three wells were calculated. Repeated experiments gave
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